BioStem Technologies: COO Andrew Smith-Van Vurst exercised 250,000 shares

What happened Andrew Smith-Van Vurst, the chief operating officer, reported exercise or conversion of derivatives on Oct 07, 2026. The filing shows acquisition of 250,000 shares at $2.00 per share for $500,000 (code M) and a disposition/conversion of 250,000 shares at $0.00 per share (code M, derivative).

Key details

• Transaction date(s) and price(s): Oct 07, 2026 — 250,000 shares acquired at $2.00; Oct 07, 2026 — 250,000 shares disposed/converted at $0.00.
• Transaction code: M (exercise or conversion of derivative) for both entries.
• Filing date: Oct 09, 2026.
• Shares owned after the transaction: not specified in the provided filing details.
• Relevant footnotes from the filing: F1 (Series A-1 convertible preferred shares convertible 1-for-1 into common stock at holder majority option), F2 (Series A-1 have no expiration date), F3 (Series A-1 shares were omitted from the reporting person's Form 3 filed Aug 14, 2026).

Why it may matter These were exercises or conversions of derivatives; the filing shows one cash exercise at $2.00 per share and one conversion/disposition recorded at $0.00 per share and does not report a market sale of the shares. A filing does not show why the insider traded or why the company acted.